Proteases induce changes in fibrocyte marker expression through activation of PAR-1 and PAR-2.

<p>PBMC were cultured as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0138748#pone.0138748.g001" target="_blank">Fig 1</a>, and after five days of treatment by PAR agonists, proteases, or proteases in the presence of PAR-1 or PAR-2 inhibitors, were analyzed as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0138748#pone.0138748.g001" target="_blank">Fig 1B</a>. <b>(A)</b> CCR7 positive fibrocytes, <b>(B)</b> CD163 positive fibrocytes, <b>(C)</b> CD206 positive fibrocytes, and <b>(D)</b> fibronectin positive fibrocytes. Values are mean ± SEM, n = 6. * indicates p < .05 and *** indicates p < .001 compared to the no-protease control (paired two-tailed t-tests).